Are current selection and isolation techniques in cell line development too harsh for your cells?
Do you need higher viability and faster insights into…
Single-cell analysis is revolutionizing drug development by revealing hidden differences within cell populations, offering crucial insights for targeted…
In our first webinar of 2024, Dr. Nora Fekete-Drimusz, Head of Biology at ARRALYZE, introduced our innovative technology and its applications in single cell…
Visit us at Booth #712 for a live demo of CellShepherd®, our latest multifunctional platform for single-cell research and finalist of the New Product Award.
Visit us at Booth Nr 4331 to experience firsthand the advanced capabilities of CellShepherd® through live demonstrations of its single cell imaging technology!
Welcome to the exciting world of ARRALYZE, a biotech company on a mission to help make groundbreaking advancements in the field of biotechnology. Today, we are…
Modern drug development has expanded from chemist-made substances to biologics and cell-based therapies. Despite the progress of the last two decades, we are…
Arralyze is an AI powered high throughput screening platform that automates workflows using machine learning models to detect, distinguish and count cells. But…
Microfluidic devices have long made their way out of the laboratory and are being used for a wide variety of applications. However, the materials used are still…
Natural killer (NK) cells are a class of cytotoxic cells that are part of the innate immune system. They provide a rapid response to virus infections,…
ARRALYZE uses so many disruptive approaches that sometimes we have to confirm the fact that we are actually doing all these things in just one machine. This…
Very exciting times! Not only did we exhibit for the first time at the SLAS but also – like many others – could not wait to participate in in-person events…
The advancement of ARRALYZE is progressing in leaps and bounds, and another important building block was put into operation today with the opening of the…
Dr. Robin A. Krüger
